TheraRadar
← Back
Data updated: Jun 28, 2026

PHARMACIA AND UPJOHN

Big Pharma

PHARMACIA AND UPJOHN is a major pharmaceutical company focused on Dermatology, Infectious Disease, Respiratory.

1942
Since
58
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
6 Small Molecules

PHARMACIA AND UPJOHN's Key Drugs

PHARMACIA AND UPJOHN's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

PHARMACIA AND UPJOHN's Recent FDA Approvals

New NDA/BLA approvals for PHARMACIA AND UPJOHN over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PHARMACIA AND UPJOHN's Therapeutic Areas

PHARMACIA AND UPJOHN's approved drugs and pipeline span 5 therapeutic areas, led by Dermatology and Infectious Disease, across 0 biologic and 6 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Dermatology 36%
4 drugs
Infectious Disease 27%
3 drugs
Respiratory 18%
2 drugs
Immunology 9%
1 drugs
Metabolic 9%
1 drugs

PHARMACIA AND UPJOHN's Top Competitors

PHARMACIA AND UPJOHN's closest competitors by therapeutic-area and drug-target overlap include GSK, Pfizer, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

PHARMACIA AND UPJOHN Pipeline Snapshot

Active clinical trials for PHARMACIA AND UPJOHN across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Dermatology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling